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How the NHS measures up to other health systems
Debate about how to improve the NHS has been handicapped by a lack of suitable comparative
data about the functioning of other health systems. David Ingleby and colleagues examine two
recent reports by the Commonwealth Fund
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The government’s plans for reorganising the English National
Health Service have sparked heated discussions about the
performance of the UK health system in comparison with that
of other countries. Politicians favouring reform have emphasised
real and perceived shortcomings of the NHS, while opponents
have lauded its successes. Objective data have been sadly
lacking in much of this debate. Arbitrary examples of good or
bad performance from the UK and various other countries have
been thrown back and forth, often using totally incommensurable
data. Two new publications from the Commonwealth Fund, a
NewYork based health policy institute, shed somemuch needed
light on these questions.1 2 We analyse the data and discuss the
strengths and weaknesses of the NHS in the light of current
proposals for reform.
The studies
The first study applied uniform criteria to assess health systems
in 14 high income countries (Australia, Canada, Denmark,
France, Italy, Japan, Germany, the Netherlands, New Zealand,
Norway, Sweden, Switzerland, the UK, and the United States).
Most of the data came from telephone interviews carried out in
2010with over 19 000 randomly chosen adults from 11 countries
(1511 in the UK).3 4 Samples were weighted to ensure that they
were representative of the general population; to minimise
possible response biases, questions were as detailed and factual
as possible. These data were supplemented by information
published by the Organisation for Economic Cooperation and
Development5 and from a recent study on mortality amenable
to healthcare.6
The second publication was based on telephone interviews
conducted in 2011 in the same 11 countries as in the first study
and used the same methods and asked many of the same
questions. This time, however, the sample consisted of over 18
000 “sicker” patients (1001 in the UK) who were in fair or poor
health, had recently been in hospital, or had had major surgery
or a serious illness or injury in the past year. Sixty two per cent
of those interviewed were aged 50 or over. This is an important
group because in the US, for example, 89% of total health
spending goes on the sickest 30% of the population.
Health system survey
We used the raw figures in the first report to compare countries.
We could make only simple comparisons because of the limited
number of countries studied. Nevertheless, some interesting
results emerged. Although the UK seems to deserve criticism
in specific areas, these are outnumbered by the areas in which
it does well. Moreover, the levels of public confidence and
satisfaction measured in the UK were higher than in any other
country (tables 1⇓ and 2⇓).
Spending
One of the most striking comparisons concerns cost. The UK
has one of the least expensive health systems among the
countries studied: annual costs (after adjustment for the cost of
living) are $3487 (£2220; €2652) per person compared with an
average of $4342—a difference of 20%. By contrast, costs per
person in the US are twice as high as in the other countries
studied.
The data also confirm that the NHS is effectively “free at the
point of delivery.” Only 5% of UK respondents had experienced
financial barriers to accessing healthcare in the previous two
years, compared with an average of 16% in other
countries—including some in which healthcare is also free in
theory. A third of US respondents had experienced financial
barriers such as out of pocket charges and high insurance
premiums.
Countries differed in how they invest their resources. Per capita
expenditure on drugs is 2.5 times higher in the US (where the
lobbying power of the pharmaceutical industry has blocked
price controls) than in the UK, and provision of magnetic
resonance imaging machines per million population differs
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widely: 43 in Japan, 26 in the US, and only six in the UK. This
is a widely used proxy for expenditure on high technology.
Regrettably, no figures were available concerning UK
expenditure on hospitals; the US leads here with $2475 per
capita compared with an average of $1480 in the 11 other
countries.
Quality
The first report lists 20 indicators of health system performance
that cover accessibility, safety, coordination of care, chronic
care management, primary care, mortality, and prevention (few
data were available for Japan, Italy, and Denmark).1 An
additional question concerning confidence in the treatment
offered was included in the original survey,3 which we have
also included in our table 1⇓ because of its relevance to this
article. We ranked scores on these indicators and report below
the position of the UK on each. More information about the
indicators is available from the original report.1
The UK did well in 13 areas and badly in five; it was best in
seven areas and worst in two (table 1⇓). However, in the two
areas where the UK does worst, cancer survival and measles
immunisation, other factors need to be taken into account.
Cancer registration in the UK covers the entire population,
whereas in many other countries registers cover relatively small
geographical areas that may not be nationally representative.7
Cancer survival rates in the US are artefactually increased by
the systematic exclusion of poor people and African Americans
from the Surveillance Epidemiology and End Results register.8
Nevertheless, cancer survival has historically been worse in the
UK than in the best performing countries. A recent study has
attributed this to the much more limited resources available for
diagnosis and treatment,9 although outcomes have been
improving rapidly since the introduction of the National Cancer
Plan.10
Measles immunisation in the UK is a special case, having been
negatively influenced by the publication of Wakefield and
colleagues’ misleading scientific paper, which gave rise to
widespread public concern about the safety of the MMR
vaccine.11 By contrast, the UK achieves the highest rate of
influenza immunisation.
Satisfaction
Table 1⇓ shows that 92% of respondents in the UK were
confident that they would receive the most effective treatment
if they became seriously ill. This was the highest percentage of
any country studied. Further encouraging results for the NHS
concerned public satisfaction and the nature of improvements
that respondents felt to be necessary. In a question about how
well the health system worked, the UK had the highest
proportion of respondents who thought “On the whole, the
systemworks pretty well and only minor changes are necessary
to make it work better” and the lowest score for “Our healthcare
system has so much wrong with it that we need to completely
rebuild it” (table 2⇓). We know from longitudinal data that
levels of satisfaction with the NHS in England reached an all
time high in 2009.12
Survey of sicker patients
The second publication, reporting data collected in 2011 from
sicker healthcare users, focused on access to care and questions
concerning howwell the care was organised and delivered.2 The
results broadly confirmed the findings of the first publication,
with the UK obtaining first or second place on most of the
variables studied.
The finding that financial barriers were lower in the UK than
anywhere else is unsurprising, but the UK also did well in other
areas. It achieved the best scores on obtaining after hours care
or a same day appointment with a doctor or nurse (tying with
Switzerland on the first of these). In the UK, the regular doctor
or place of care was most likely to have information about the
patient’s medical history and to get involved in coordinating
care. More British patients (74%) than in any other country had
what the report calls a medical home—caregivers who knew
them and gave person centred primary care. The report ascribes
a key role to medical homes in improving delivery of care,
especially for people who are chronically ill.
In this survey British doctors gained the highest scores for their
willingness to inform and involve the patient. This was a major
improvement since the 2008 Commonwealth Fund survey, in
which British doctors were given lower scores than doctors in
any other country except France. In 2011 British doctors also
gained second place for “spending enough time with patients,
encouraging questions, and explaining things carefully”; for the
willingness of specialists to share decision making with the
patient; and for the readiness of health workers to contact sick
patients to see how things were going. Top scores were obtained
for the engagement of patients in management of chronic
conditions and for openness to telephone contacts between visits.
The last area explored in the second publication concerned gaps
in planning discharge from hospital. UK caregivers achieved
top scores for giving patients instructions on their treatment and
information about whom to contact when needed, as well as for
arranging follow-up visits. The UK gained second place for
providing written care plans and giving clear instructions on
medication; the overall assessment of the coordination of
discharge planning was the highest achieved by any country.
The UK had the lowest percentage of patients who had
experienced medical or other errors in the past two years, as
well as the highest percentage whose prescriptions were kept
under review.
In summary, the UK’s performance as evaluated by “sicker”
patients was best or second best in almost all respects studied.
The only discordant note concerned patients with diabetes, heart
disorders, and hypertension, who were least likely to have their
blood pressure “controlled last time it was checked.” The authors
of the second publication conclude that “compared with UK
patients’ responses to earlier surveys, those who responded to
this year’s survey reportedmarked improvements in care access,
management, and communication.” They linked these findings
to policy interventions introduced in recent years.
Discussion
The Commonwealth Fund data indicate that accessibility of
healthcare in the UK is better than in any other country studied
(box). Care also seems to be better organised, safer, and more
patient centred. These publications report less information about
outcome measures, however, and what they do report tends to
be less favourable to the UK, except in preventive care for
diabetes, where scores are highest. Three measures warrant
particular concern: deaths amenable to healthcare, survival rates
for breast cancer, and survival after acute myocardial infarction.
Of course, no outcome measure is a pure indication of the
effectiveness of healthcare. The characteristics of patients and
their illnesses also influence outcomes. (This, incidentally, may
also explain some of the regional disparities in outcomes within
countries.)
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Key conclusions from Commonwealth Fund data
• The NHS outperforms other high income countries on many measures despite spending much less than most of them
• It enjoys the highest levels of public confidence and satisfaction of all the countries studied
• The effects of increased investment and policy improvements over the past decade are clearly visible
Nevertheless, concern about NHS clinical outcomes seems
justified. The analysis of 16 high income nations6 quoted in the
first publication showed that UK deaths amenable to healthcare
were higher in 2006-7 than anywhere else except the US; these
deaths were down 35% on the even more alarming figures
recorded nine years earlier, but there was still much room for
improvement.
Making care more accessible and better organised, as has clearly
been achieved over the past few years, is likely to improve
outcomes. However, investment in high technology equipment
and more expensive treatments is low in the UK, despite an
increase in spending between 2000 and 2010. Given that health
expenditure in the UK is still relatively low, there is a case for
increasing spending on diagnosis and treatment to the level of
other comparable countries.
Conclusions
The results reported here do not support complacency about the
current performance of the health system in the UK. They show
that, like all health systems, it has its strengths and weaknesses.
They do, however, cast serious doubt on any claim that there is
widespread popular support for radical reform. Improvements
are needed, but continuation and expansion of the measures
already set in motion—more of the same—seems to be a better
formula than totally rebuilding a system that, by international
standards, already works remarkably well.
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Tables
Table 1 | Ranking of UK health system compared with other countries in Commonwealth Fund surveys
Range of scores (%)UK score (%)No of countries with dataUK rankItem
UK does well
70-9292111Users are confident they would receive the most effective treatment if they
became seriously ill3
8-188111Low rate of errors3
67-316781Preventive care for diabetics3
89-1289101Use of clinical outcomes data3
96-296101Use of patient satisfaction data3
89-1089141Financial incentives, targeted support*
9-369101Avoids amputation in diabetic patients5
33-6838112Problems getting care after hours3
14-3420112Problems coordinating tests, records3
38-715082Gaps in hospital discharge planning3
98-6296102Guidelines used for diabetes*
12-321483Specialist not informed about history3
77-6173103Influenza immunisation over age 655
UK does neither well nor badly
93-4570114Able to get appointment on same/next day3
5-4119115Waited ≥2 months for specialist appointment3
0-2521118Waited ≥4 months for elective surgery3
UK does badly
43-585187Regular doctor always informs and involves patient†
2.9-6.66.387Deaths after admission for acute myocardial infarction (per 100 patients)‡5
55-968387Amenable mortality per 100 000‡6
87-97871010Measles immunisation rate5
79-917977Breast cancer 5 year survival rate‡5
*2009 Commonwealth Fund international health policy survey.
†2008 Commonwealth Fund international health policy survey of sicker adults.
‡2007 data.
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Table 2| Public views of the health system in 2010 in UK and 10 other countries (% of respondents)3
Others (mean)UK
3962Works well, minor changes needed
4734Fundamental changes needed
133Needs to be completely rebuilt
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